Next Post

$500m CartiHeal sale to go ahead after FDA approval granted

&#13 US orthologics business Bioventus (Nasdaq: BVS) can now carry on with its $500 million acquisition of CartiHeal, right after the Israeli health-related product organization gained Food and drug administration clearance for its implants for the treatment of weakened cartilage. Bioventus signed an arrangement to purchase CartiHeal previous July, for […]